53
Participants
Start Date
December 31, 2015
Primary Completion Date
February 29, 2020
Study Completion Date
May 31, 2021
IMO-2125
Drug: IMO-2125 Intratumoral injection administered as 9 doses on Weeks 1, 2, 3, 5, 8, 11, 17, 23, and 29.
Ipilimumab
4 doses administered intravenously at a dose of 3 mg/kg over 90 minutes on Weeks 2, 5, 8, and 11.
Icahn School Of Medicine at Mount Sinai, New York
Roswell Park Cancer Institute, Buffalo
Moffitt Cancer Center Research Institute, Tampa
Vanderbilt-Ingram Cancer Center, Nashville
Gabrail Cancer Center, Canton
University of Iowa Hospitals and Clinics, Iowa City
University of Kansas Cancer Center, Westwood
MD Anderson Cancer Center, Houston
University of Utah- Huntsman Cancer Institute, Salt Lake City
The University of Arizona Cancer Center, Tucson
Lead Sponsor
Idera Pharmaceuticals, Inc.
INDUSTRY